Test & Trial | IPCIUM

TEST & TRIAL IPCIUM'S MyPERSN PLATFORM

INVITATION TO DIGITAL HEALTH FESTIVAL ATTENDEES

MyPERSN Platform is uniquely designed to support individuals & their Treatment Team better manage Type 2 Diabetes (T2D) through the integration of novel CDMiQ assessment & intervention tool, automated onboarding, live dashboard link access to health outcomes, evidence-based Goal Setting, integrated Learning Management System & future Lived Experience Peer-to-Peer Group Program.

BENEFITS

Automated onboarding
Treatment Team collaboration
Customisable & gamified questionnaire
Live dashboard access
Unique dashboard & health outcomes insights
Integrated Learning Management System

"CDMiQ was enjoyable and very educational. I learnt many things I needed to learn."
- A.M., Woodridge QLD

ONBOARD HERE

Simply scan the QR Code to start testing and trialling MyPERSN Platform.

"The Platform is very slick"
- R.H., Parkinson QLD

DOWNLOAD OUR DIGITAL HEALTH FESTIVAL TEST & TRIAL FLYER HERE

CDMiQ PILOT TRIAL - PHASE 1

CDMiQ

Put simply, CDMiQ is a digitally integrated health assessment tool, which has been developed to provide individuals living with chronic disease (such as Type 2 Diabetes (T2D)) with the capability to easily compare and share individual health data together with their entire treatment team. Providing individuals and their Health Care Team with unique insights into how they are managing their condition; how they are tracking against Optimum Treatment Guidelines; and what their individual risk factors are across multiple diabetes related diseases.

WHY STUDY TYPE 2 DIABETES (T2D)?

Pre-diabetes is recognised as the first phase of Type 2 Diabetes (T2D) development and if not identified early and managed appropriately through lifestyle changes, can quickly progress to T2D. Type 2 Diabetes Mellitus (T2DM) is a chronic disease which develops over time and is caused by many factors, including genetics and lifestyle behaviours, is closely linked to a number of concurrent chronic diseases (co-morbidities). Research suggests that T2D can be prevented or delayed in up to 58% of cases, by the adoption of healthy lifestyle choices and by reducing/limiting unhealthy behaviours. T2D is also referred to as Non-Insulin Dependent Diabetes and if not managed well, can rapidly progresses in severity, significantly increasing the risk of developing / further progressing diabetes related health complications. Which is why it is extremely important for individuals with T2D to understand how their lifestyle choices and health behaviours positively and negatively impact their condition and what steps need to be taken, in order to gain control over their modifiable risk factors. Implementing and following an evidence based T2D management plan takes a collaborative a supportive from the entire treatment team to reduce and slow down progression of the disease.

IPCIUM's T2D PILOT TRIAL

Our experienced team of researchers are undertaking a Pilot Trial to assess CDMiQ’s utility in providing individuals living with T2D (and their treatment team) with unique insights into the various challenges and barriers experienced around chronic disease management, treatment plan & Optimum Treatment Guideline adherence, risk factor identification and mitigation, and clinical health outcomes allowing for improved decision making, through the CDMiQ (Chronic Disease Management Intelligence Quotient) assessment and live, web enabled dashboard.

We hope that through this Pilot Trial we will be able to;

Test how effective CDMiQ is at capturing, scoring, scaling, displaying individual health outcome measures and treatment team data.
Test how user friendly CDMiQ is for individuals with chronic disease. Specifically, how easy it is to use, navigate and interact with the CDMiQ platform.
Test how user friendly CDMiQ is for health care professionals. Specifically, how easy it is to compare individual health outcome measure within the live, web enabled dashboard. Optimum Treatment Guidelines and concurrent chronic disease risk factors.
Test how effective CDMiQ is at identifying measurable improvements across a number of health outcome indicators, for individuals with living with T2D.
Test individuals to see if their health outcomes improve as a result of using CDMiQ’s web enabled platform and live dashboard reporting environment together with their chosen treatment team.

WHO IS ABLE TO PARTICIPATE IN THE CURRENT T2D PILOT TRIAL?

We are seeking participants for the current CDMiQ T2D Pilot Trial, who meet the inclusion criteria listed below.

Existing medical diagnosis of Type 2 Diabetes (T2D) for 12 months or more (diagnosis indicated by the presence of one or more of the following factors):
- Attendance at a GP Clinic / Hospital / Emergency centre with a hyperglycaemic crisis (high blood sugar event)
- Single elevated Fasting Blood Glucose reading ≥7.0 mmol/L
- Single random Blood Glucose reading ≥11.1 mmol/L
- Single HbA1c ≥6.5%
Sex: Male / Female
Age range: 35 – 75 years
Currently / previously being treated for T2D within the Australian health care system
Have seen a GP for review of their T2D within the last 6-12 months
Have ability to access T2D related pathology results within the last 6 months
Mobile phone access to submit an Expression of Interest and ability to complete the Pilot Trial self-referral process using QR code
Able to complete CDMiQ assessment within 7 days of commencement, at two points in time approximately eight weeks apart
Willingness to sign informed consent form and a willingness to participate and comply with Pilot Trial requirements

Ideally, participants seeking to join the current CDMiQ T2D Pilot Trial would also meet the desirable criteria listed below:

Desire to improve own clinical health outcomes, risk factors and optimal treatment guideline adherence
Passionate about improving the future of healthcare for other individuals with T2D
Sound literacy, basic computing & technology skills (internet based applications, emails, texts & Zoom calls)

WHO IS UNABLE TO PARTICIPATE IN THE CURRENT T2D PILOT TRIAL?

Participants excluded from participating in the current CDMiQ T2D Pilot Trial, satisfy one or more of the exclusion criteria listed below.

Women lactating, breastfeeding or pregnant (or of childbearing potential who are not willing to avoid becoming pregnant for the entirety of the Pilot Trial study)
Have recently undergone major surgery or chemotherapy within the last 6 months
Anticipate undergoing major surgery or chemotherapy within the next 3 months
Currently undergoing dialysis / diagnosed with Chronic Kidney Disease
Currently employed within the healthcare / software development / health technology sectors.
Currently involved in a clinical study or enrolled in a structured lifestyle management / health & wellbeing program (beyond normal GP directed treatment)
Recently diagnosed with significant medical condition requiring significant investigation and treatment such as heart failure, kidney failure, cancer
Participants who have received an investigational / new drug within the last 4 weeks
Participants with a history of a psychological illness or other conditions, which would likely interfere with their ability to participate effectively within the study / meet the Pilot Trial requirement.

To receive an information pack or to participate in the current T2D CDMiQ Pilot Trial, simply register your Expression of Interest (EOI) with one of our Pilot Partners by downloading one of the flyers & scanning the Pilot Partner specific QR code below. Alternatively, email hello@ipcium.com for further information.